紫杉醇联合卡铂治疗晚期非小细胞肺癌

Paclitaxel Combined with Carboplatin for Advanced Non-small Cell Lung Cancer

目的探讨紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效及毒性。方法对48例应用紫杉醇联合卡铂治疗的晚期非小细胞肺癌患者进行分析。用药方案如下:紫杉醇165mg/m2,根据肌酐清除率计算卡铂的用量[AUC(药-时曲线下面积)为5],每3周1次为1个周期,2个周期以上评价疗效及毒副作用。结果紫衫醇联合卡铂的总有效率为41.6%,其中初治者有效率42.1%,复治者有效率40.0%。中位生存期为18.2个月,主要毒副反应为骨髓抑制及肌肉酸痛,绝大多数为轻度反应,患者耐受性良好。结论紫杉醇联合卡铂治疗晚期非小细胞肺癌是一种安全、有效、值得推广应用的化疗方案。

Objective To study the efficacy and adverse effect of Paclitaxel combined with Carboplatin for advanced non-small cell lung cancer（NSCLC）. Methods Retrospective study was used to the clinical data of 48 cases of NSCLC treated by Paclitaxel and Carboplatin. Paclitaxel was given at a dose of 165 mg/m^2 and Carboplatin at a dose for AUC 5. The chemotherapy was repeated every 21 days. The efficacy and toxicity were evaluated after 2 cycles or more. Results The overall response rate of this treatment was 41.6% in which the response rate was 42, 1% for the initial treatment and 40.0）% for the retreatment. The median survival time was 18. 2 months. Bone marrow depression and muscular soreness were the main adverse effects which was less and most of the patients could tolerate. Conclusions Combination of Paclitaxel and Carboplatin is a kind of safe and effective chemotherapeutic regimen for the treatment of NSCLC and is worth being used widely.